Compared with postoperative stereotactic radiation therapy, an investigational intraoperative RT approach could significantly reduce local tumor recurrence and improve survival in patients with newly diagnosed operable brain metastases.
The new device, designed to perform mitral valve repair in patients with functional MR, was co-invented by cardiologist Samir Kapadia, MD, and surgeon Jose Navia, MD.
The late-breaking five-year results of the Evolut Low-Risk Trial presented at ACC.25 showed positive results for the Evolut TAVR system when compared to SAVR.
Former American College of Cardiology president Hadley Wilson, MD, executive vice chair of Atrium Health Sanger Heart and Vascular Institute, explains his main takeaway messages from the ACC 2025 late-breaking trials.